QMS Medical Approves Healthcare Demerger, Separate Listing and BeamOptics Acquisition
QMS Medical Allied Services Limited (QMSMEDI) has approved a Composite Scheme of Arrangement that will reorganise its healthcare-services business into a separate entity, while also approving the proposed acquisition of 100% of BeamOptics Scientific Private Limited.
The decisions were approved by the company’s Board of Directors on September 25, 2026, based on recommendations from the Audit Committee and Independent Directors Committee.
The proposed restructuring remains subject to approvals from shareholders, creditors, stock exchanges, the National Company Law Tribunal (NCLT) and other applicable authorities.
Healthcare Services Business to Be Demerged
Under the proposed scheme, the healthcare-services businesses of QMS Medical Allied Services Limited and Health Care at Home India Private Limited (HCAH) will be transferred to Saarathi Healthcare Private Limited, the resulting company.
The businesses being transferred are involved in areas including:
- Patient support programmes
- Patient access programmes
- Disease management programmes
- Preventive healthcare
- Healthcare outcome improvement services
QMS said the healthcare-services business had turnover of ₹37.17 crore as of March 31, 2026, representing 24.41% of QMS’s total turnover for the immediately preceding financial year.
Proposed Separate Listing of Healthcare Business
One of the most important aspects of the scheme is that the resulting company, Saarathi Healthcare, proposes to seek listing of its equity shares on the National Stock Exchange of India.
The listing would be pursued under the applicable exemption provisions and subject to regulatory approvals.
If the scheme becomes effective, QMS shareholders will receive shares in the resulting company on a 1:1 basis.
In other words, for every one fully paid-up QMS equity share held, the shareholder will receive one fully paid-up equity share of Saarathi Healthcare.
There is no cash consideration under this part of the scheme.
HCAH Shareholders Will Also Receive Shares
Shares in the resulting company will also be issued to eligible shareholders and security holders of Health Care at Home India Private Limited under specified exchange ratios.
For example, HCAH Class A equity shareholders will receive:
209 Saarathi Healthcare shares for every 3,500 HCAH Class A equity shares held.
Separate ratios have been specified for different classes of HCAH preference shares and CCPS.
The scheme assumes exercise of HCAH ESOPs on a fully diluted basis for the resulting company’s post-arrangement shareholding.
Proposed Post-Arrangement Shareholding
Based on the company’s disclosure, the resulting company is expected to have:
- Promoters: 40.5%
- Public: 59.5%
- Total: 100%
The proposed post-arrangement share capital is 3,25,00,066 shares.
Why Is QMS Demerging the Business?
QMS said the healthcare-services businesses of QMS and HCAH operate in a similar line of business to Saarathi.
Combining these businesses into a separate entity is intended to provide:
- Focused management of the healthcare-services business
- Greater operational efficiency
- Better resource utilisation
- Potentially faster growth
- Greater scale and market presence
- Operational and business synergies
The company also said a separate listed healthcare-services entity could provide a dedicated platform to pursue growth strategies.
QMS Signs Merger Cooperation and Shareholders’ Agreements
QMS has also entered into a Merger Cooperation Agreement with the relevant investors, promoter and group entities.
A separate Shareholders’ Agreement has been executed by Saarathi Healthcare with the investors and promoter.
The shareholders’ agreement provides for various rights, including provisions relating to board representation, reserved matters, pre-emptive rights, transfer restrictions and tag-along rights.
The company stated that these agreements will not affect the management or control of the listed QMS entity.
QMS to Acquire 100% of BeamOptics Scientific
In another major development, QMS has agreed to acquire 100% of BeamOptics Scientific Private Limited.
The company has entered into a Binding Memorandum of Understanding (MOU) with the relevant parties dated September 25, 2026.
BeamOptics designs and manufactures advanced optics, diagnostics and analytical instruments used in areas including:
- Healthcare
- Dairy quality
- Food safety
- Pharmaceutical screening
Acquisition Value Yet to Be Determined
The consideration for the acquisition has not yet been finalised.
QMS said the consideration could be through:
- Cash
- Share swap
- A combination of cash and share swap
The final consideration will be determined based on a valuation report issued by an independent valuer.
QMS will acquire 100% of BeamOptics Scientific.
BeamOptics Financials
BeamOptics Scientific was incorporated on October 25, 2023, with its registered office in Pune, Maharashtra.
Its disclosed turnover was:
- FY2025-26: ₹1.1381 crore
- FY2024-25: Nil
- FY2023-24: Nil
The company is therefore still at an early stage based on the disclosed revenue history.
QMS expects the transaction to expand its total addressable market in value-added healthcare businesses.
Acquisition Timeline
The proposed BeamOptics acquisition is subject to the terms and conditions of the transaction documents and the NCLT approval of the composite scheme.
The company has indicated a target completion date of November 30, 2027, or such later date as may be mutually agreed.
What This Means for QMS Medical Investors
The September 25 announcement combines business restructuring and expansion.
The proposed demerger could result in QMS’s healthcare-services business being housed in a separate entity with a proposed NSE listing, while QMS is also seeking to expand its healthcare-products and technology exposure through BeamOptics.
However, several important elements are still pending.
The composite scheme requires multiple regulatory and stakeholder approvals, while the BeamOptics acquisition valuation has not yet been determined.
Therefore, the financial impact of the transaction cannot yet be quantified from this disclosure alone.
Key Takeaways
- Company: QMS Medical Allied Services
- Healthcare business demerger: Approved
- Resulting company: Saarathi Healthcare Private Limited
- QMS shareholder entitlement: 1 Saarathi share for every 1 QMS share
- Proposed listing: NSE
- QMS healthcare business turnover: ₹37.17 crore
- Share of QMS turnover: 24.41%
- BeamOptics acquisition: 100%
- BeamOptics FY2025-26 turnover: ₹1.1381 crore
- BeamOptics acquisition consideration: Yet to be determined
- Valuation: Independent valuation report
- Target completion: On or before November 30, 2027, subject to conditions and approvals
FutureSense India View
For stock-market investors, the most important development is the proposed separation and listing of the healthcare-services business, because QMS shareholders are proposed to receive shares in the resulting company on a 1:1 basis.
The proposed BeamOptics acquisition adds another dimension by expanding QMS into healthcare products and technology, but investors will need to wait for the independent valuation and final transaction terms before assessing its financial impact.
The entire restructuring is still subject to regulatory and shareholder approvals, so the September 25 announcement should be viewed as the beginning of the proposed process rather than its completion.
Source: QMS Medical Allied Services Limited exchange filing dated September 25, 2026.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should conduct their own research and consider their financial objectives and risk tolerance before making investment decisions.
